WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

Zhongtai Securities: Maintain "Buy" rating on WuXi Biologics (02269); capacity expansion to accelerate commercialization projects is expected to continue https://hk.investing.com/news/stock-market-news/article-249098

Essence Securities: Rating WuXi Biologics (02269) "Buy-A" to Achieve High Growth in 22H1 https://finance.sina.cn/hkstock/ggpj/2022-08-19/detail-imizirav8789043.d.html?from=wap

WuXi Biologics (02269) Subsidiary WuXi XDC Granted a Total of 9,052,800 Share Options https://finance.sina.cn/hkstock/gsxw/2022-08-18/detail-imizirav8726980.d.html?from=wap

http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1205548/1

WuXi Biologics Reports Strong 2022 Interim Results https://www.prnewswire.com/news-releases/wuxi-biologics-reports-strong-2022-interim-results-301607649.html Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2 Million Adjusted Net Profit Rose by 60.9% to RMB2,914.9 Million Total Backlog Reached US$18,467 Million ...

"HSI Deepens Loss to Over 350 Pts; CN Consumers, Drugs In Sell-off; Anta, BYD, Techtronic Ind, WuXi Bio Sink Over 4-6% AASTOCKS Financial News - Latest News" http://www.aastocks.com/en/stocks/news/aafn-con/now.1203517/latest-news

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1202446/company-news/HK6

WuXi Biologics (02269) rose over 4%, reached strategic cooperation with AstraZeneca for the localized production of new crown prevention and neutralizing antibody Enshide https://finance.sina.cn/hkstock/sckxjfx/2022-08-04/detail-imizmscv4789918.d.html?from=wap

WuXi Biologics Steps into the Harvest Period, Actively Strengthens the Global... https://www.donews.com/article/detail/6337/44980.html

Buoyed By Bumper Profits, WuXi Biologics Seeks To Bolster Global Supply Chain https://seekingalpha.com/article/4526161-buoyed-by-bumper-profits-wuxi-biologics-seeks-to-bolster-global-supply-chain Summary • Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would jump as much as 37%. • The provider of outsourced pharmaceutical services has delivered on bullish market hopes of rapid earnings growth. • It plans to invest around $1.44 billion in a new research and production hub in Singapore to strengthen its global supply network. ...

https://finance.sina.cn/hkstock/ggyw/2022-07-26/detail-imizirav5455315.d.html?from=wap

Morgan Stanley: Maintain "Overweight" rating on WuXi Biologics (02269) with a target price of HK$119.8 https://finance.sina.cn/hkstock/ggpj/2022-07-25/detail-imizmscv3446393.d.html?from=wap

"CICC: Maintain WuXi Biologics (02269) "Outperform the Industry" Rating Target Price Raised to HK$96.8 Provider Zhitong Finance" https://m.hk.investing.com/news/stock-market-news/article-242935

"Biologics firm sees good growth | The Standard" https://www.thestandard.com.hk/section-news/section/2/243786/Biologics-firm-sees-good-growth

WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore https://www.prnewswire.co.uk/news-releases/wuxi-biologics-plans-to-build-a-comprehensive-crdmo-center-in-singapore-828331481.html • This investment will establish a cutting-edge, fully integrated CRDMO center in Singapore, including a research and development service center and large-scale drug substance and drug product manufacturing facilities for biologics • The investment strengthens WuXi Biologics' global research, development and manufacturing network with more robust nodes to meet the growing demand from clients worldwide for end-to-end services, and continues to enable its Global Dual Sourcing strategy ...